High riskMid capEducational sample dataset

Laurus Labs

LAURUSLABS · NSE & BSE · Pharmaceuticals · Pharma CDMO & APIs

Current price

₹520.00

+0.60%FY24 (illustrative)

Illustrative / demo price - not live.

Compare Learn this concept

About the company

A pharmaceutical company focused on APIs, formulations and contract development.

Origin & history

Founded in 2005, Laurus Labs scaled into a leading API and CDMO player.

Founded

2005

Headquarters

Hyderabad

Business segments

APIs50.0%
Formulations35.0%
CDMO15.0%

Competitive position (moat)

Integrated API-to-formulation capability and CDMO relationships.

Governance

Promoter-led with professional management.

Promoter holding

32.4%

Institutional holding

25.0%

Why it's interesting

A growth-oriented pharma CDMO with exposure to global generic and innovation demand.

What to verify

  • CDMO order pipeline
  • API price competition
  • Leverage and working capital

Key risks

  • API pricing
  • Competition
  • Leverage

Valuation snapshot

Market cap

₹28,000 cr

Total value of all shares: price multiplied by shares outstanding.

P/E

45.0

Price to earnings: how much you pay per rupee of profit.

P/B

5.0

Price to book: how the price compares to net asset value per share.

EV/EBITDA

22.0

Enterprise value to operating profit: a valuation that accounts for debt and cash.

Dividend yield

0.2%

Annual dividend per share as a percentage of the price.

Profitability

Revenue

₹7,000 cr

EBITDA

₹1,500 cr

Net income

₹620 cr

EPS

₹12.00

EBITDA margin

21.4%

Net margin

8.9%

ROE

12.0%

ROCE

14.0%

Revenue growth

15.0%

Balance sheet health

Debt/equity

0.9

Total debt divided by shareholders' equity: how leveraged the company is.

Cash

₹1,000 cr

Cash and equivalents on the balance sheet.

Interest coverage

3.0

How many times operating profit covers interest expense.

Dividends & returns

Dividend yield

0.2%

Dividend yield is the annual payout as a share of the price. A higher yield can signal a mature, cash-generative business - or a falling price. Check the payout history before reading too much into it.

Growth trend

Revenue growth

15.0%

Revenue growth shows how fast the top line is expanding. Pair it with margin trends to see whether growth is turning into profit.

Ownership

Promoter holding

32.4%

Share held by the founding family or group.

Institutional holding

25.0%

Share held by mutual funds, insurers and foreign institutions.

Placeholders - verify in the shareholding pattern.

Key catalysts

  • CDMO growth
  • New products

Red flags

  • API pricing
  • Leverage

52-week range

52-week low

₹350.00

Lowest price in the 52-week range.

52-week high

₹600.00

Highest price in the 52-week range.